Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 people in total, split into two groups of five. One group was planned to receive open-label abatacept (a medicine used to dampen the immune system) and then continue on a 10 mg/kg dose, while the other group was planned to continue on a 5 mg/kg dose. The trial was looking at adverse events (unwanted or harmful experiences during the study) as its main focus, as well as several secondary measures related to eye health — including changes in vision sharpness, whether participants were able to reduce their other immune-suppressing medicines, and whether signs of inflammation in the eye improved. Of the 10 people who started, 3 completed the study in one group and 1 in the other, meaning 7 people did not finish the trial. The reported data shows that for the primary outcome — the number of participants who experienced adverse events — zero participants were recorded across all three groups (those on 10 mg/kg, those on 5 mg/kg, and those in the open-label phase). For the secondary outcomes, all of which were measured at the 24-week mark when everyone was still on the same open-label treatment, the reported data shows that zero out of the participants showed an improvement of two or more lines in their best-corrected vision (a standard eye chart measure). Six participants were reported to have reduced their dose of corticosteroids or other immune-suppressing medicines by at least 50%. Four participants were reported to have shown a reduction in signs of eye inflammation based on clinical assessments. It is worth noting that this was a very small trial with only 10 participants, and a large proportion did not complete the study, which limits what can be drawn from these numbers. The reported data shows only what was observed and recorded in this specific group of people under the conditions of this trial. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a serious eye condition caused by the immune system attacking the eye (called autoimmune uveitis) that is threatening your vision
- You have already tried prednisone (a steroid medication) and at least one other medication that suppresses the immune system, and these have not worked well enough, or you were unable to tolerate them due to side effects
Who may not be able to join:
- You have another serious health condition that could affect your ability to safely take part in the trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.